Prilenia

At Prilenia Therapeutics, we are at the forefront of neuroprotective care, pioneering groundbreaking technology to revolutionize the treatment of devastating neurodegenerative diseases. Our core mission is to develop and deliver transformative medicines that can slow the progression of conditions like Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS). Through rigorous scientific exploration and an unwavering commitment to innovation, we are advancing our lead candidate, pridopidine, a first-in-class, orally administered, and highly selective sigma-1 receptor (S1R) agonist. This novel mechanism is designed to regulate critical neuroprotective pathways that are often compromised in neurodegenerative disorders, offering a new beacon of hope for patients and their families worldwide. Our research is driven by compelling scientific findings that demonstrate the activation of the S1R can restore essential neural pathways, potentially preserving function and improving the quality of life for those affected.

Our innovation focus extends beyond a single compound. We are building a future of connected care, fostering collaborations and partnerships to accelerate progress and ensure sustainable access to our therapies. Prilenia's approach is rooted in bold research and a deep understanding of the underlying biology of neurodegeneration. By harnessing the brain's intrinsic neuroprotective capabilities, we aim to move beyond symptomatic treatment and fundamentally alter the course of these relentless diseases. We are a highly virtual and flexible organization, with a dynamic team operating across the globe, united by a simple but urgent mission. Our work has led to pridopidine receiving Orphan Drug designation in the U.S. and EU for both HD and ALS, as well as Fast Track designation from the FDA for HD. As we advance through late-stage clinical trials and prepare for potential regulatory approvals, we continue to push the boundaries of what's possible in neuroscience, striving to bring brighter futures to patients in desperate need of new therapeutic options.